DE19647853A1 - Verbindungen mit verbesserter knorpel- und/oder knocheninduzierender Aktivität - Google Patents
Verbindungen mit verbesserter knorpel- und/oder knocheninduzierender AktivitätInfo
- Publication number
- DE19647853A1 DE19647853A1 DE19647853A DE19647853A DE19647853A1 DE 19647853 A1 DE19647853 A1 DE 19647853A1 DE 19647853 A DE19647853 A DE 19647853A DE 19647853 A DE19647853 A DE 19647853A DE 19647853 A1 DE19647853 A1 DE 19647853A1
- Authority
- DE
- Germany
- Prior art keywords
- protein
- bone
- implant material
- cartilage
- matrix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 68
- 210000000845 cartilage Anatomy 0.000 title claims abstract description 32
- 230000001939 inductive effect Effects 0.000 title claims abstract description 20
- 150000001875 compounds Chemical class 0.000 title claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 93
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 92
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims abstract description 46
- 239000011159 matrix material Substances 0.000 claims abstract description 43
- 239000000463 material Substances 0.000 claims abstract description 40
- 239000007943 implant Substances 0.000 claims abstract description 37
- 239000001506 calcium phosphate Substances 0.000 claims abstract description 25
- 239000000919 ceramic Substances 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 21
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 230000000975 bioactive effect Effects 0.000 claims abstract description 16
- 235000011010 calcium phosphates Nutrition 0.000 claims abstract description 9
- 229910000389 calcium phosphate Inorganic materials 0.000 claims abstract description 7
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 20
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 20
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 16
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 16
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 11
- 230000006378 damage Effects 0.000 claims description 8
- 238000009826 distribution Methods 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 210000002808 connective tissue Anatomy 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 238000013270 controlled release Methods 0.000 claims description 4
- 239000000539 dimer Substances 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 239000011877 solvent mixture Substances 0.000 claims description 4
- 206010011732 Cyst Diseases 0.000 claims description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 238000002144 chemical decomposition reaction Methods 0.000 claims description 3
- 238000002316 cosmetic surgery Methods 0.000 claims description 3
- 208000031513 cyst Diseases 0.000 claims description 3
- 230000007547 defect Effects 0.000 claims description 3
- 230000007850 degeneration Effects 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 102000037865 fusion proteins Human genes 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 3
- 238000011065 in-situ storage Methods 0.000 claims description 3
- 230000008595 infiltration Effects 0.000 claims description 3
- 238000001764 infiltration Methods 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 201000001245 periodontitis Diseases 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 208000010392 Bone Fractures Diseases 0.000 claims description 2
- 239000002537 cosmetic Substances 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 229940102213 injectable suspension Drugs 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 230000002188 osteogenic effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 238000000859 sublimation Methods 0.000 claims description 2
- 230000008022 sublimation Effects 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 101100472152 Trypanosoma brucei brucei (strain 927/4 GUTat10.1) REL1 gene Proteins 0.000 abstract description 11
- 210000001519 tissue Anatomy 0.000 abstract description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000036244 malformation Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 74
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 15
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 15
- 239000012071 phase Substances 0.000 description 14
- 230000002138 osteoinductive effect Effects 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 8
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 229940112869 bone morphogenetic protein Drugs 0.000 description 8
- 238000005245 sintering Methods 0.000 description 8
- 239000011148 porous material Substances 0.000 description 7
- 102100040895 Growth/differentiation factor 10 Human genes 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 239000004068 calcium phosphate ceramic Substances 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 101710194458 Growth/differentiation factor 10 Proteins 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 230000011164 ossification Effects 0.000 description 4
- 235000004252 protein component Nutrition 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010059616 Activins Proteins 0.000 description 3
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000000488 activin Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 2
- 102000005606 Activins Human genes 0.000 description 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 2
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 2
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 2
- 102100022545 Bone morphogenetic protein 8B Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010041881 Growth Differentiation Factor 10 Proteins 0.000 description 2
- 108010090254 Growth Differentiation Factor 5 Proteins 0.000 description 2
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 2
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 description 2
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000002746 Inhibins Human genes 0.000 description 2
- 108010004250 Inhibins Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102000043168 TGF-beta family Human genes 0.000 description 2
- 108091085018 TGF-beta family Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000000893 inhibin Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 238000010587 phase diagram Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000242757 Anthozoa Species 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 description 1
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 1
- 101710118482 Bone morphogenetic protein 10 Proteins 0.000 description 1
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 1
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 102100040897 Embryonic growth/differentiation factor 1 Human genes 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010090296 Growth Differentiation Factor 1 Proteins 0.000 description 1
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 1
- 108010090293 Growth Differentiation Factor 3 Proteins 0.000 description 1
- 108010090250 Growth Differentiation Factor 6 Proteins 0.000 description 1
- 102000004858 Growth differentiation factor-9 Human genes 0.000 description 1
- 108090001086 Growth differentiation factor-9 Proteins 0.000 description 1
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 1
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 description 1
- 101710204281 Growth/differentiation factor 6 Proteins 0.000 description 1
- 102100035363 Growth/differentiation factor 7 Human genes 0.000 description 1
- 101710204283 Growth/differentiation factor 7 Proteins 0.000 description 1
- 241000424725 Heide Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 description 1
- 101001023988 Homo sapiens Growth/differentiation factor 5 Proteins 0.000 description 1
- 102100026818 Inhibin beta E chain Human genes 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102000007453 TGF-beta Superfamily Proteins Human genes 0.000 description 1
- 108010085004 TGF-beta Superfamily Proteins Proteins 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 208000015100 cartilage disease Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000005365 phosphate glass Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000009418 renovation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001180 sulfating effect Effects 0.000 description 1
- 238000000352 supercritical drying Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 description 1
- FDFYYWMHPJTGEO-UHFFFAOYSA-K tetracalcium;phosphate Chemical class [Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O FDFYYWMHPJTGEO-UHFFFAOYSA-K 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 108010042974 transforming growth factor beta4 Proteins 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/42—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix
- A61L27/425—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix of phosphorus containing material, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials Engineering (AREA)
- Composite Materials (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19647853A DE19647853A1 (de) | 1996-11-19 | 1996-11-19 | Verbindungen mit verbesserter knorpel- und/oder knocheninduzierender Aktivität |
| ES97951919T ES2210592T3 (es) | 1996-11-19 | 1997-11-19 | Compuestos con una mejorada actividad inductora de cartilago y/o hueso. |
| DE59711220T DE59711220D1 (de) | 1996-11-19 | 1997-11-19 | Verbindungen mit verbesserter knorpel- und/oder knocheninduzierender aktivität |
| AU55533/98A AU5553398A (en) | 1996-11-19 | 1997-11-19 | Compounds with improved inductive effect on cartilage and bones |
| JP52321598A JP3807749B2 (ja) | 1996-11-19 | 1997-11-19 | 改良された軟骨誘導活性および／または硬骨誘導活性を有する複合体 |
| PCT/EP1997/006463 WO1998021972A2 (de) | 1996-11-19 | 1997-11-19 | Verbindungen mit verbesserter knorpel- und/oder knocheninduzierender aktivität |
| EP97951919A EP0942758B1 (de) | 1996-11-19 | 1997-11-19 | Verbindungen mit verbesserter knorpel- und/oder knocheninduzierender aktivität |
| US11/080,494 US7365051B2 (en) | 1996-11-19 | 2005-03-16 | Compounds with improved cartilage-inducing and/or bone-inducing activity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19647853A DE19647853A1 (de) | 1996-11-19 | 1996-11-19 | Verbindungen mit verbesserter knorpel- und/oder knocheninduzierender Aktivität |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE19647853A1 true DE19647853A1 (de) | 1998-05-20 |
Family
ID=7812132
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19647853A Withdrawn DE19647853A1 (de) | 1996-11-19 | 1996-11-19 | Verbindungen mit verbesserter knorpel- und/oder knocheninduzierender Aktivität |
| DE59711220T Revoked DE59711220D1 (de) | 1996-11-19 | 1997-11-19 | Verbindungen mit verbesserter knorpel- und/oder knocheninduzierender aktivität |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE59711220T Revoked DE59711220D1 (de) | 1996-11-19 | 1997-11-19 | Verbindungen mit verbesserter knorpel- und/oder knocheninduzierender aktivität |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7365051B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP0942758B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP3807749B2 (cg-RX-API-DMAC10.html) |
| AU (1) | AU5553398A (cg-RX-API-DMAC10.html) |
| DE (2) | DE19647853A1 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2210592T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO1998021972A2 (cg-RX-API-DMAC10.html) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19944681A1 (de) * | 1999-08-20 | 2001-03-01 | Metz Stavenhagen Peter | Knochenersatzstoff zur Implantation im menschlichen oder tierischen Körper |
| WO2003043673A1 (en) * | 2001-11-19 | 2003-05-30 | Scil Technology Gmbh | Device having osteoinductive and osteoconductive properties |
| EP1604694A1 (en) * | 2004-06-09 | 2005-12-14 | Scil Technology GmbH | Composite device having osteoinductive and osteoconductive properties |
| DE102005060761A1 (de) * | 2005-12-16 | 2007-06-21 | Alexakis, Antonis, Dr. med. dent. | Formteil zur Neubildung von Knochenmaterial |
| EP2033598A1 (en) * | 2007-09-05 | 2009-03-11 | DePuy-Biotech Gmbh | Calcium phosphate based delivery of growth and differentiation factors to compromised bone |
| US7763270B2 (en) | 2002-09-10 | 2010-07-27 | Scil Technology Gmbh | Metal implant coated under reduced oxygen concentration with osteoinductive protein |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6267798A (en) † | 1997-02-07 | 1998-08-26 | Stryker Corporation | Matrix-free osteogenic devices, implants and methods of use thereof |
| GB2366738B (en) * | 2000-03-10 | 2004-03-03 | Technology Finance Corp | Implant including a body of non-resorbable bioactive material |
| US20060034803A1 (en) * | 2002-11-07 | 2006-02-16 | Masanori Nakasu | Therapeutic device for osteogenesis |
| US7067123B2 (en) | 2003-04-29 | 2006-06-27 | Musculoskeletal Transplant Foundation | Glue for cartilage repair |
| US7901457B2 (en) * | 2003-05-16 | 2011-03-08 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
| EP1604693A1 (en) | 2004-06-09 | 2005-12-14 | Scil Technology GmbH | In situ forming scaffold, its manufacturing and use |
| US20090319045A1 (en) | 2004-10-12 | 2009-12-24 | Truncale Katherine G | Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles |
| US7837740B2 (en) | 2007-01-24 | 2010-11-23 | Musculoskeletal Transplant Foundation | Two piece cancellous construct for cartilage repair |
| US7815926B2 (en) | 2005-07-11 | 2010-10-19 | Musculoskeletal Transplant Foundation | Implant for articular cartilage repair |
| CA2623106C (en) | 2005-09-19 | 2013-12-24 | Histogenics Corporation | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof |
| WO2007068489A2 (en) * | 2005-12-14 | 2007-06-21 | Scil Technology Gmbh | A moldable biomaterial for bone regeneration |
| EP1880731A1 (en) | 2006-07-18 | 2008-01-23 | BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH | Human growth and differentiation factor GDF-5 |
| US7723291B2 (en) * | 2006-07-27 | 2010-05-25 | Warsaw Orthopedic, Inc. | Release of BMP, bioactive agents and/or cells via a pump into a carrier matrix |
| SI3345607T1 (sl) * | 2006-12-29 | 2023-03-31 | Ossifi-Mab Llc | Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE |
| SI2121142T1 (sl) * | 2007-01-25 | 2012-12-31 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | Uporaba GDF-5 za izboljšanje ali vzdrževanje videza kože |
| US8435551B2 (en) | 2007-03-06 | 2013-05-07 | Musculoskeletal Transplant Foundation | Cancellous construct with support ring for repair of osteochondral defects |
| KR100991203B1 (ko) * | 2010-05-10 | 2010-11-01 | 심영복 | 골형성 단백질의 정제 방법 |
| EP2537538A1 (en) * | 2011-06-22 | 2012-12-26 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH | Bioresorbable Wound Dressing |
| EP2602264A1 (en) | 2011-12-05 | 2013-06-12 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH | GDF-5 mutant for inducing cartilage formation |
| US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
| US10919948B2 (en) | 2016-12-30 | 2021-02-16 | Biogend Therapeutics Co., Ltd. | Recombinant polypeptides, compositions, and methods thereof |
| US11324806B2 (en) | 2018-10-19 | 2022-05-10 | Warsaw Orthopedic, Inc. | Sustained delivery of a growth differentiation factor |
| CN114786707A (zh) | 2019-12-18 | 2022-07-22 | 默克专利股份公司 | Gdf-5突变体用于治疗疼痛和软骨破坏的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4596574A (en) * | 1984-05-14 | 1986-06-24 | The Regents Of The University Of California | Biodegradable porous ceramic delivery system for bone morphogenetic protein |
| US4681763A (en) * | 1985-06-11 | 1987-07-21 | University Of Medicine And Dentistry Of New Jersey | Composition for stimulating bone growth |
| DE3810803A1 (de) * | 1988-03-30 | 1989-10-12 | Battelle Institut E V | Verfahren zur herstellung eines synthetischen knochenmaterials mit koerpereigenen eigenschaften |
| WO1991005802A1 (en) | 1989-10-17 | 1991-05-02 | Creative Biomolecules, Inc. | Osteogenic devices |
| IL110589A0 (en) * | 1993-08-10 | 1994-11-11 | Bioph Biotech Entw Pharm Gmbh | Growth/differentiation factor of the TGF- beta family |
| GB2302656B (en) | 1994-05-24 | 1998-03-18 | Implico Bv | A biomaterial and bone implant for bone repair and replacement |
| US5866155A (en) * | 1996-11-20 | 1999-02-02 | Allegheny Health, Education And Research Foundation | Methods for using microsphere polymers in bone replacement matrices and composition produced thereby |
-
1996
- 1996-11-19 DE DE19647853A patent/DE19647853A1/de not_active Withdrawn
-
1997
- 1997-11-19 JP JP52321598A patent/JP3807749B2/ja not_active Expired - Fee Related
- 1997-11-19 EP EP97951919A patent/EP0942758B1/de not_active Revoked
- 1997-11-19 ES ES97951919T patent/ES2210592T3/es not_active Expired - Lifetime
- 1997-11-19 AU AU55533/98A patent/AU5553398A/en not_active Abandoned
- 1997-11-19 DE DE59711220T patent/DE59711220D1/de not_active Revoked
- 1997-11-19 WO PCT/EP1997/006463 patent/WO1998021972A2/de not_active Ceased
-
2005
- 2005-03-16 US US11/080,494 patent/US7365051B2/en not_active Expired - Fee Related
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19944681A1 (de) * | 1999-08-20 | 2001-03-01 | Metz Stavenhagen Peter | Knochenersatzstoff zur Implantation im menschlichen oder tierischen Körper |
| WO2003043673A1 (en) * | 2001-11-19 | 2003-05-30 | Scil Technology Gmbh | Device having osteoinductive and osteoconductive properties |
| US8546334B2 (en) | 2001-11-19 | 2013-10-01 | Scil Technology Gmbh | Device having osteoinductive and osteoconductive properties |
| US7763270B2 (en) | 2002-09-10 | 2010-07-27 | Scil Technology Gmbh | Metal implant coated under reduced oxygen concentration with osteoinductive protein |
| US8257728B2 (en) | 2002-09-10 | 2012-09-04 | Scil Technology Gmbh | Metal implant coated under reduced oxygen concentration with osteoinductive protein |
| EP1604694A1 (en) * | 2004-06-09 | 2005-12-14 | Scil Technology GmbH | Composite device having osteoinductive and osteoconductive properties |
| DE102005060761A1 (de) * | 2005-12-16 | 2007-06-21 | Alexakis, Antonis, Dr. med. dent. | Formteil zur Neubildung von Knochenmaterial |
| DE102005060761B4 (de) * | 2005-12-16 | 2007-10-25 | Alexakis, Antonis, Dr. med. dent. | Formteil zur Neubildung von Knochenmaterial |
| EP2033598A1 (en) * | 2007-09-05 | 2009-03-11 | DePuy-Biotech Gmbh | Calcium phosphate based delivery of growth and differentiation factors to compromised bone |
| WO2009030483A3 (en) * | 2007-09-05 | 2009-04-23 | Depuy Biotech Gmbh | Calcium phosphate based delivery of growth and differentiation factors to compromised bone |
Also Published As
| Publication number | Publication date |
|---|---|
| DE59711220D1 (de) | 2004-02-19 |
| EP0942758B1 (de) | 2004-01-14 |
| JP3807749B2 (ja) | 2006-08-09 |
| AU5553398A (en) | 1998-06-10 |
| ES2210592T3 (es) | 2004-07-01 |
| US7365051B2 (en) | 2008-04-29 |
| WO1998021972A2 (de) | 1998-05-28 |
| US20050169965A1 (en) | 2005-08-04 |
| JP2001505097A (ja) | 2001-04-17 |
| WO1998021972A3 (de) | 1998-09-17 |
| EP0942758A2 (de) | 1999-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0942758B1 (de) | Verbindungen mit verbesserter knorpel- und/oder knocheninduzierender aktivität | |
| EP0605799B1 (de) | Hohlendoprothesen mit knochenwachstumsfördernder Füllung | |
| DE60004710T2 (de) | Mineral-polymer hybrid-zusammensetzung | |
| DE60020526T2 (de) | Osteogene pastenzusammensetzungen und ihre verwendung | |
| DE3588120T2 (de) | Kollagenknochenersatzmaterial | |
| DE69432596T2 (de) | Zusammensetzungen für verabreichung von osteogenen proteinen | |
| DE60006356T2 (de) | Hochmineralisierte osteogene schwammzusammensetzungen und ihre verwendung | |
| DE69632790T2 (de) | Zusammensetzungen unter verwendung von morphogenen proteinen und stimulationsfaktoren | |
| DE60023754T2 (de) | Künstlicher kalciumphosphatknochen als osteokonduktives und biologisch abbauba res knochenersatzmaterial | |
| DE69531779T3 (de) | Herstellung von autogenen körperersatzteilen | |
| EP0520237B1 (de) | Knochenersatzmaterial mit Fibroblasten-Wachstums-Faktoren | |
| DE69927512T2 (de) | Verwendung von op-1 zur herstellung einer pharmazeutischen zusammensetzung zur reparatur von nicht-gelenksknorpeldefekten eines säugers | |
| DE69434122T2 (de) | Osteogenisches produkt und verwendung | |
| DE69922312T2 (de) | Keramikmaterial zur Osteoinduktion enthaltend Mikroporen an der Öberfläche von Makroporen | |
| DE69403439T2 (de) | Tgf-beta zusammensetzung zum herbeiführen von knochenwachstum | |
| DE60205937T3 (de) | Methode zur Herstellung einer homogen beschichtete Vorrichtung mit osteoinduktiven und osteokonduktiven Eigenschaft | |
| DE60021388T2 (de) | Monomeres protein der tgf-beta familie | |
| EP1121161A1 (de) | Zusammensetzung zur implantation in den menschlichen und tierischen körper | |
| EP2209505B1 (de) | Verfahren zur herstellung von mit wachstumsfaktoren beladenen partikeln sowie die so erhaltenen partikel | |
| DE68918043T2 (de) | Knochenersatzmaterial und Knochenzement. | |
| Rueger | Bone replacement materials–state of the art and the way ahead: Heutiger Stand und Ausblick | |
| EP1819371A2 (de) | Bioresorbierbares und oberflächen-mineralisiertes material zur füllung von knochendefekten | |
| WO1997023612A2 (de) | Zielgerichtete verbindungen mit knorpel- und/oder knocheninduzierender aktivität | |
| WO2008107122A2 (de) | Zusammensetzung zur behandlung von knochen- und/oder knorpeldefekten | |
| EP3609548B9 (de) | Natives knochenersatzmaterial zur förderung der osteogenese, verfahren zu dessen herstellung und verwendungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8127 | New person/name/address of the applicant |
Owner name: BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWI |
|
| 8110 | Request for examination paragraph 44 | ||
| R119 | Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee |
Effective date: 20140603 |